The Prague Post - Study shows how fast kilos return after ending weight-loss drugs

EUR -
AED 4.110102
AFN 72.735804
ALL 90.771756
AMD 403.674395
ANG 2.002782
AOA 1026.129808
ARS 1723.64436
AUD 1.592813
AWG 2.014212
AZN 1.904927
BAM 1.955209
BBD 2.253929
BDT 138.656856
BGN 1.955835
BHD 0.422269
BIF 3355.341938
BMD 1.119007
BND 1.432854
BOB 13.266872
BRL 6.060984
BSD 1.119067
BTN 106.460874
BWP 15.437197
BYN 3.291776
BYR 21932.533595
BZD 2.2507
CAD 1.568232
CDF 2590.501063
CHF 0.925105
CLF 0.028028
CLP 1106.597134
CNY 7.472783
CNH 7.461
COP 3520.887806
CRC 509.441485
CUC 1.119007
CUP 26.857883
CVE 110.231686
CZK 24.347742
DJF 198.870182
DKK 7.474271
DOP 68.489301
DZD 151.14379
EGP 62.949947
ERN 16.785102
ETB 183.297966
FJD 2.501761
FKP 0.83669
GBP 0.837828
GEL 2.898111
GGP 0.83669
GHS 13.008422
GIP 0.83669
GMD 82.806903
GNF 9904.051072
GTQ 8.554338
GYD 234.49913
HKD 8.779162
HNL 30.04492
HRK 7.534163
HTG 146.574393
HUF 367.311714
IDR 20304.378677
ILS 3.451179
IMP 0.83669
INR 106.467624
IQD 1695.387623
IRR 2050440.114277
ISK 136.395521
JEP 0.83669
JMD 177.666306
JOD 0.793356
JPY 176.164685
KES 145.302691
KGS 97.857287
KHR 4562.580333
KMF 491.794032
KPW 1007.106091
KRW 1483.176106
KWD 0.347709
KYD 0.93261
KZT 504.642978
LAK 25186.163213
LBP 100212.218523
LKR 371.837624
LRD 190.240806
LSL 18.610709
LTL 3.304136
LVL 0.676876
LYD 7.175831
MAD 10.992029
MDL 20.109743
MGA 5082.418583
MKD 61.505844
MMK 2349.748126
MNT 4027.299553
MOP 9.043186
MRU 45.0004
MUR 52.739
MVR 17.299538
MWK 1940.496206
MXN 20.76762
MYR 4.572377
MZN 71.516168
NAD 18.610875
NGN 1506.608692
NIO 41.177555
NOK 10.41595
NPR 170.336999
NZD 1.966378
OMR 0.430254
PAB 1.119052
PEN 3.8579
PGK 5.090439
PHP 71.534192
PKR 309.67581
PLN 4.403488
PYG 6451.050377
QAR 4.090764
RON 5.348291
RSD 117.513651
RUB 90.417779
RWF 1654.585168
SAR 4.190386
SBD 9.03551
SCR 15.50473
SDG 673.078465
SEK 11.124268
SGD 1.432737
SHP 0.836234
SLE 25.680921
SLL 23465.018351
SOS 639.501016
SRD 42.177578
STD 23161.181827
STN 24.492707
SVC 9.792084
SYP 14549.32627
SZL 18.604211
THB 37.789418
TJS 10.32348
TMT 3.927714
TND 3.34289
TOP 2.6943
TRY 55.683456
TTD 7.605633
TWD 36.43341
TZS 2959.776408
UAH 51.091431
UGX 5013.529625
USD 1.119007
UYU 44.876438
UZS 13392.952409
VES 984.489771
VND 28917.933644
VUV 132.928606
WST 3.097178
XAF 655.957
XAG 0.020676
XAU 0.000278300022
XCD 3.024172
XCG 2.016872
XDR 0.791196
XOF 655.957
XPF 119.331742
YER 264.1965
ZAR 18.608406
ZMK 10072.402218
ZMW 22.531989
ZWL 360.319738
SSP 6429.029586
MXV 2.343019
  • GSK

    0.3500

    51.1

    +0.68%

  • NGG

    -0.0900

    81.77

    -0.11%

  • BCC

    -2.3000

    75.44

    -3.05%

  • RIO

    0.3000

    83.72

    +0.36%

  • BCE

    -0.1500

    20.25

    -0.74%

  • BTI

    0.6200

    60.1

    +1.03%

  • CMSD

    -0.1600

    19.62

    -0.82%

  • BP

    -0.7900

    50.53

    -1.56%

  • CMSC

    0.0010

    19.601

    +0.01%

  • RYCEF

    0.6000

    16.1

    +3.73%

  • RBGPF

    0.3800

    70.53

    +0.54%

  • AZN

    0.5700

    172.06

    +0.33%

  • JRI

    0.1000

    10.85

    +0.92%

  • VOD

    -0.0400

    15.7

    -0.25%

  • RELX

    -0.3600

    40.18

    -0.9%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: Armend NIMANI - AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

D.Kovar--TPP